Skip to main navigation menu Skip to main content Skip to site footer

CYP1A1, TNFα Genes and environmental factors associated with gastric cancer in patients from Pasto-Colombia

Genes CYP1A1, FNTα y factores ambientales asociados a cáncer gástrico en pacientes de Pasto-Colombia




Section
Artículo Original

How to Cite
Paz, C. O., Mena Huertas, J., Fernández Izquierdo, P., Burbano-Rosero, E. M., & Pazos, A. (2024). CYP1A1, TNFα Genes and environmental factors associated with gastric cancer in patients from Pasto-Colombia. NOVA, 23(43). https://doi.org/10.22490/24629448.8553

Dimensions
PlumX
license
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Licencia Creative Commons

NOVA by http://www.unicolmayor.edu.co/publicaciones/index.php/nova is distributed under a license creative commons non comertial-atribution-withoutderive 4.0 international.

Furthermore, the authors keep their property intellectual rights over the articles.

 

Introduction. In Pasto, Nariño, Colombian, the gastric cancer (GC) incidence is one of the highest in the world. It is known that in the GC the CYP1A1 and TNFα human susceptibility to cancer genes are involved along to environmental factors to pathogenesis GC. Although the relationship among environmental factors and human genetic predisposition to gastric cancer is still unknown.

Aim. To evaluate the environmental factors and GC human genetic predisposition (CYP1A1 and TNFα genes) association in patients with GC diagnose in Pasto. Methods. This is a cross-sectional, descriptive and observational study that included 10 gastric cancers positive and surviving cases. We studied the genetic predisposition to gastric by the  CYP1A1 and TNFα genetic biomarkers. The genetic variability was determined by SNPs and RFLP in silico by gene sequences bioinformatic analysis. The environmental and familiar factors were analyzed through surveys. Results. In all our cases (n=10) we found gene risk alleles in high frequency (TNFα 40%, CYP1A1 50%). We observed that the 60% of GC genetic susceptibility were significate associated to age (p<0.05). While the environmental, genetics and familiar did not showed associated to CYP1A1 and TNFα prevalence. An association of smoking with a low genetic variability of the TNFα risk gene was found. Conclusion: The high-risk gene frequencies CYP1A1 and TNFα suggest the presence of gastric cancer human susceptibility in GC diagnosed patients. In the cases observed, the human susceptibility to GC is associated to advanced age and smoking.


Article visits 13 | PDF visits 10


Downloads

Download data is not yet available.

1. Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019;14(1):26-38.

2. International Agency for Research on Cancer. Global Cancer Observatory [Internet]. Lyon; 2022 [fecha de acceso 22 de diciembre de 2022]. Disponible en: https://gco.iarc.fr/

3. Abengozar R, Sharma A, Sharma R. Gastric cancer: lessons learned from high-incidence geographic regions. J Gastrointest Oncol. 2021;12(S2):S350-60.

4. Calderón - Gerstein WS, Torres - Samaniego G. High altitude and cancer: An old controversy. Respir Physiol Neurobiol. 2021;289:1-12.

5. Pardo C, de Vries E, Buitrago L, Gamboa O. Atlas de mortalidad por cáncer en Colombia. 4 ed. Bogotá D. C: Instituto Nacional de Cancerología; 2017.

6. Yépez MC, Bravo LM, Jurado DM, Mena SJ, Casas HM. Incidencia y mortalidad por cáncer en el municipio de Pasto - Colombia, 2013-2017. Colomb Med. 2022;53(1):1-16.

7. Gámez D, Dueñas O, Álvarez M. Actualización sobre los factores de riesgo asociados a la mortalidad del cáncer gástrico. Revista Habanera de Ciencias Médicas. 2021;20(5):1-8.

8. Mao Y, Yang W, Qi Q, Yu F, Wang T, Zhang H, et al. Blood groups A and AB are associated with increased gastric cancer risk: evidence from a large genetic study and systematic review. BMC Cancer. 2019;19(1):1-9.

9. Yusefi AR, Bagheri K, Bastani P, Radinmanesh M, Kavosi Z. Risk Factors for Gastric Cancer: A Systematic Review. Asian Pac J Cancer Prev. 2018;19(3):591-603.

10. Maddineni G, Xie JJ, Brahmbhatt B, Mutha P. Diet and carcinogenesis of gastric cancer. Curr Opin Gastroenterol. 2022;38(6):588-91.

11. Mannion A, Dzink-Fox J, Shen Z, Piazuelo MB, Wilson KT, Correa P, et al. Helicobacter pylori Antimicrobial Resistance and Gene Variants in High- and Low-Gastric-Cancer-Risk Populations. J Clin Microbiol. 2021;59(5):e03203-03220.

12. Osorio M, Olivert M, de Pasos J, Quiñones A, Vega M, Ortega A. Caracterización de la infección por Helicobacter pylori en pacientes con úlcera gástrica. MediSur. 2009;7(6):3-11.

13. Lyons K, Le LC, Pham YTH, Borron C, Park JY, Tran CTD, et al. Gastric cancer: epidemiology, biology, and prevention: a mini review. Eur J Cancer Prev. 2019;28(5):397-412.

14. Yepez Y, Ricaurte PA, Bedoya A, Berbesi DY. Lesiones precursoras de malignidad gástrica y su asociación con hábitos alimentarios. Rev Colomb Gastroenterol. 2017;32(3):209-15.

15. Caguazango JC, Pazos ÁJ. Microbiota según la topografía gástrica en pacientes con bajo y con alto riesgo de cáncer gástrico en Nariño, Colombia. Biomedica. 2019;39(Supl. 2):157-71.

16. Carlosama-Rosero YH, Acosta-Astaiza CP, Sierra-Torres CH, Bolaños-Bravo HJ. Helicobacter pylori genotypes associated with gastric cancer and dysplasia in Colombian patients. Rev Gastroenterol Mex (Engl Ed). 2022;87(2):181-7.

17. Rosero-Rojas SC, Chaleal-Cultid JA, Pazos-Moncayo ÁJ, Rosero-Galindo CY. Polimorfismos IL1B-511 y TNF-A-308 en una población infectada con Helicobacter pylori de una zona de bajo riesgo de cáncer gástrico en Nariño-Colombia. Infectio. 2020;24(2):81-7.

18. Patil M, Datkhile K, Gudur A, Gudur R, Patil S. Single-nucleotide polymorphism in CYP1A1, CYP1B1, CYP2B6, CYP2C8, and CYP2C9 genes and their association with gastrointestinal cancer: A hospital-based case-control study. J Cancer Res Ther. 2023; XX(XX):1-8.

19. Zhao F, Su J, Lun S, Hou Y, Duan L, Wang N, et al. Association between polymorphisms in the CYP1A1, CYP2E1 and GSTM1 genes, and smoking, alcohol and upper digestive tract carcinomas in a high‑incidence area of northern China. Oncol Lett. 2019; 18(2):1267–77.

20. Xue H, Lu Y, Xue Z, Lin B, Chen J, Tang F, et al. The effect of CYP1A1 and CYP1A2 polymorphisms on gastric cancer risk among different ethnicities: a systematic review and meta-analysis. Tumour Biol. 2014;35(5):4741-56.

21. Portillo JD, Araujo LM, Melo JM, Carlosama Rosero YH. Características sociodemográficas e histopatológicas en pacientes con cáncer gástrico en una población con alto riesgo en Colombia. Rev colomb Gastroenterol. 2021;36(1):18-23.

22. Gómez M, Otero W, Ruiz X. Factores de riesgo para cáncer gástrico en pacientes colombianos. Rev Colomb Gastroenterol. 2009;24(2):134-43.

23. Lee K, Cáceres D, Varela N, Csendes A, Ríos H, Quiñones L. Variantes alélicas de CYP1A1 y GSTM1 como biomarcadores de susceptibilidad a cáncer gástrico: influencia de los hábitos tabáquico y alcohólico. Rev Med Chil. 2006;134(9):1107-15.

24. Castaño E, Parra H. Dejar de fumar: Factor protector de Cáncer Gástrico. Hacia la promoción de la salud. 2007;12(1):125-32.

25. Sambrook J, Fritsch E, Maniatis T. Molecular Cloning: A Laboratory Manual. 2 ed. New York: Cold Spring Harbor Laboratory Press; 1989.

26. Torres MM, Acosta CP, Sicard DM, Groot de Restrepo H. Susceptibilidad genética y riesgo de cáncer gástrico en una población del Cauca. Biomedica. 2004;24(2):153-62.

27. Díaz AM. Estudio genotípico del citocromo P450 en una cohorte de pacientes con Cáncer de Pulmón en el Área Sanitaria de Mérida [Tesis doctoral]. Badajoz: Universidad de Extremadura; 2003.

28. Pavão R, Soares R, Albuquerque A, De Souza M, Da Rocha P, Jácome S, et al. Fatores de risco do câncer gástrico: Revisão de literatura. Res Soc Dev. 2022;11(3):1-7.

29. Ajani JA, Lee J, Sano T, Janjigian YY, Fan D, Song S. Gastric adenocarcinoma. Nat Rev Dis Primers. 2017;3(1):1-19.

30. Camargo MC, Goto Y, Zabaleta J, Morgan DR, Correa P, Rabkin CS. Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012;21(1):20-38.

31. Jackson M, Marks L, May GHW, Wilson JB. The genetic basis of disease. Essays Biochem. 2018;62(5):643-723.

32. Gallo E, Cabaleiro T, Román M, Abad-Santos F, Daudén E. Estudio de los polimorfismos genéticos de la región promotora del TNF-α en pacientes españoles afectos de psoriasis. Actas Dermosifiliogr. 2012;103(4): 301-307.

33. Muñoz RB, Albores A. Polimorfismos y exposición a xenobióticos en el asma infantil. Gac Med Mex. 2011;147(1):38-47.

34. Silva CP, Kamens HM. Cigarette smoke-induced alterations in blood: A review of research on DNA methylation and gene expression. Exp Clin Psychopharmacol. 2021;29(1):116-35.

35. Martínez P. Estudio de las propiedades de acetilcolinesterasa y butirilcolinesterasa en el tejido pulmonar humano y sus alteraciones en distintos tipos histológicos de cáncer de pulmón de células no pequeñas [Tesis doctoral]. Murcia: Universidad de Murcia; 2012.

36. Yang JP, Hyun MH, Yoon JM, Park MJ, Kim D, Park S. Association between TNF-α-308 G/A gene polymorphism and gastric cancer risk: A systematic review and meta-analysis. Cytokine. 2014;70(2):104-14.

37. Acosta O, Solano L, Oré D, Granara AS, Sandoval J, Fujita R. Polimorfismo -308 G/A en la región promotora del gen factor de necrosis tumoral alfa (TNFA) en diferentes subpoblaciones peruanas. Horizonte Médico (Lima, Peru). 2010;10(1):47-54.

38. Martínez T, Hernández G, Bravo MM, Trujillo E, Quiroga A, Robayo JC, et al. Polimorfismos genéticos de interleucinas IL-1B-511, IL-1RN, IL-10, factor de necrosis tumoral α-308 e infección por Helicobacter pylori CagA positivo en cáncer gástrico y úlcera duodenal en diferentes poblaciones en Colombia. Revista Colombiana de Cancerología. 2011;15(2):85-97.

39. Lapa M, Veloso W, Nascimento A, Peixoto A, Alvez H, Cardoso MV, et al. Association of TNFα -308G/A and IL10 -1082A/G Polymorphisms with Pulmonary Tuberculosis Susceptibility in a Brazilian population. PREPRINT (Version 1). Disponible en Research Square [https://doi.org/10.21203/rs.3.rs-2150864/v1]. 2022.

40. Mbemi A, Khanna S, Njiki S, Yedjou CG, Tchounwou PB. Impact of Gene–Environment Interactions on Cancer Development. Int J Environ Res Public Health. 2020;17(21):1-15.

41. Cavaco I, Piedade R, Msellem MI, Bjorkman A, Gil JP. Cytochrome 1A1 and 1B1 gene diversity in the Zanzibar islands. Trop Med Int Health. 2012;17(7):854-7.

42. Santos RP, Encinas F, Lasmar RB, Falagan-Lotsch P, Granjeiro JM, Penna IA. Polimorfismos nos genes MMP2, MMP13, CYP1A1, GSTM1 e EMX2 e endometriose. Femina. 2011;39(6):313-7.

43. Hendriati, Vitresia H. Polymorphisms of CYP1A1 Genes and Its Correlation with Clinical Variant of Pterygium. Borneo Epidemiology Journal. 2020;1(2):116-23.

44. Collado M. Estudio de los polimorfismos en los genes del Citocromo P450 (CYP1A1, CYP2E1 Y CYP3A4), de la Quinona Oxoreductasa (NQO1), del Glutation S-Transferasa (GSTM1 y GSTT1) y del Folato (MTHFR, TS) como factores predisponentes en las hemopatías malignas [Tesis doctoral]. Valencia: Universidad de Valencia; 2013.

45. Mota P, Moura DS, Vale MG, Coimbra H, Carvalho L, Regateiro F. Polimorfismos dos alelos m1 e m2 do gene CYP1A1: Susceptibilidade genética para o cancro do pulmão. Rev Port Pneumol. 2010;16(1):89-98.

47. Gao Z, Wyman MJ, Sella G, Przeworski M. Interpreting the Dependence of Mutation Rates on Age and Time. PLoS Biol. 2016;14(1):1-16.

48. Laconi E, Marongiu F, DeGregori J. Cancer as a disease of old age: changing mutational and microenvironmental landscapes. Br J Cancer. 2020;122(1):943-52.

49. Wu SG, Chang YL, Yu CJ, Yang PC, Shih JY. Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors. ERJ Open Res. 2017; 3(3):1-12.

50. Ondarza R. La epigenética, la otra cara de la genética. Mensaje bioquímico. 2012;36:200-11.

51. Lewandowska J, Bartoszek A. DNA methylation in cancer development, diagnosis and therapy—multiple opportunities for genotoxic agents to act as methylome disruptors or remediators. Mutagenesis. 2011;26(4):475-87.

52. Choi YJ, Kim N. Gastric cancer and family history. Korean J Intern Med. 2016;31(6):1042-53.

53. Mirandola S, Pellini F, Granuzzo E, Lorenzi M, Accordini B, Ulgelmo M, et al. Multidisciplinary management of CDH1 germinal mutation and prophylactic management hereditary lobular breast cancer: A case report. Int J Surg Case Rep. 2019; 58:92-5.

54. Ayala JC, Lotero JD. Tamización de cáncer gástrico. Universitas medica. 2013; 54 (2): 209-22.

55. Collatuzzo G, Pelucchi C, Negri E, López‐Carrillo L, Tsugane S, Hidaka A, et al. Exploring the interactions between Helicobacter pylori (Hp) infection and other risk factors of gastric cancer: A pooled analysis in the Stomach cancer Pooling (StoP) Project. Int J Cancer. 2021;149(6):1228-38.

56. Oliveros Wilches R, Facundo Navia H, Bonilla AD, Pinilla Morales R. Factores de riesgo para cáncer gástrico: ¿cuál es su papel?. Rev Colomb Gastroenterol. 2021;36(3):366-76.

57. Yi JF, Li YM, Liu T, He WT, Li X, Zhou WC, et al. Mn-SOD and CuZn-SOD polymorphisms and interactions with risk factors in gastric cancer. World J Gastroenterol. 2010;16(37):4738-46.

58. Yin J, Wu X, Li S, Li C, Guo Z. Impact of environmental factors on gastric cancer: A review of the scientific evidence, human prevention and adaptation. J Environ Sci (China). 2020;89:65-79.

Sistema OJS 3.4.0.5 - Metabiblioteca |